Ellipticine and benzo(a)pyrene increase their own metabolic activation via modulation of expression and enzymatic activity of cytochromes P450 1A1 and 1A2

Ellipticine and benzo(a)pyrene increase their own metabolic activation via modulation of expression and enzymatic activity of cytochromes P450 1A1 and 1A2 Two compounds known to covalently bind to DNA after their activation with cytochromes P450 (CYPs), carcinogenic benzo(a)pyrene (BaP) and an antineoplastic agent ellipticine, were investigated for their potential to induce CYP and NADPH:CYP reductase (POR) enzymes in rodent livers, the main target organ for DNA adduct formation. Two animal models were used in the study: (i) rats as animals mimicking the fate of ellipticine in humans and (ii) mice, especially wild-type (WT) and hepatic POR null (HRN™) mouse lines. Ellipticine and BaP induce expression of CYP1A enzymes in livers of experimental models, which leads to increase in their enzymatic activity. In addition, both compounds are capable of generating DNA adducts, predominantly in livers of studied organisms. As determined by 32P postlabelling analysis, levels of ellipticine-derived DNA adducts formed in vivo in the livers of HRN™ mice were reduced (by up to 65%) relative to levels in WT mice, indicating that POR mediated CYP enzyme activity is important for the activation of ellipticine. In contrast to these results, 6.4 fold higher DNA binding of BaP was observed in the livers of HRN™ mice than in WT mice. This finding suggests a detoxication role of CYP1A in BaP metabolism in vivo. In in vitro experiments, DNA adduct formation in calf thymus DNA was up to 25 fold higher in incubations of ellipticine or BaP with microsomes from pretreated animals than with controls. This stimulation effect was attributed to induction of CYP1A1/2 enzymes, which are responsible for oxidative activation of both compounds to the metabolites generating major DNA adducts in vitro. Taken together, these results demonstrate that by inducing CYP1A1/2, ellipticine and BaP modulate their own enzymatic metabolic activation and detoxication, thereby modulating their either pharmacological (ellipticine) and/or genotoxic potential (both compounds).

[1]  V. Arlt,et al.  Role of hepatic cytochromes P450 in bioactivation of the anticancer drug ellipticine: studies with the hepatic NADPH:cytochrome P450 reductase null mouse. , 2008, Toxicology and applied pharmacology.

[2]  V. Arlt,et al.  Metabolic activation of benzo[a]pyrene in vitro by hepatic cytochrome P450 contrasts with detoxification in vivo : experiments with Hepatic Cytochrome P450 Reductase Null mice , 2008 .

[3]  R. Vaclavikova,et al.  The Anticancer Drug Ellipticine Is a Potent Inducer of Rat Cytochromes P450 1A1 and 1A2, Thereby Modulating Its Own Metabolism , 2007, Drug Metabolism and Disposition.

[4]  E. Frei,et al.  DNA adduct formation by the anticancer drug ellipticine in human leukemia HL-60 and CCRF-CEM cells. , 2007, Cancer letters.

[5]  E. Frei,et al.  Formation and persistence of DNA adducts of anticancer drug ellipticine in rats. , 2007, Toxicology.

[6]  E. Frei,et al.  Mammalian peroxidases activate anticancer drug ellipticine to intermediates forming deoxyguanosine adducts in DNA identical to those found in vivo and generated from 12‐hydroxyellipticine and 13‐hydroxyellipticine , 2007, International journal of cancer.

[7]  E. Frei,et al.  Cytochromes P450 reconstituted with NADPH: P450 reductase mimic the activating and detoxicating metabolism of the anticancer drug ellipticine in microsomes. , 2006, Neuro endocrinology letters.

[8]  J. Hudeček,et al.  Oxidation pattern of the anticancer drug ellipticine by hepatic microsomes - similarity between human and rat systems. , 2006, General physiology and biophysics.

[9]  Eva Frei,et al.  Molecular mechanisms of antineoplastic action of an anticancer drug ellipticine. , 2006, Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia.

[10]  D. Nebert,et al.  Oral Benzo[a]pyrene in Cyp1 Knockout Mouse Lines: CYP1A1 Important in Detoxication, CYP1B1 Metabolism Required for Immune Damage Independent of Total-Body Burden and Clearance Rate , 2006, Molecular Pharmacology.

[11]  V. Arlt,et al.  Bioactivation of 3-aminobenzanthrone, a human metabolite of the environmental pollutant 3-nitrobenzanthrone: evidence for DNA adduct formation mediated by cytochrome P450 enzymes and peroxidases. , 2006, Cancer letters.

[12]  C. Wolf,et al.  The hepatic cytochrome P450 reductase null mouse as a tool to identify a successful candidate entity. , 2006, Toxicology letters.

[13]  J. Hudeček,et al.  The Effect of pH on Peroxidase-Mediated Oxidation of and DNA Adduct Formation by Ellipticine , 2006 .

[14]  Václav Martínek,et al.  Expression of cytochrome P450 1A1 and its contribution to oxidation of a potential human carcinogen 1-phenylazo-2-naphthol (Sudan I) in human livers. , 2005, Cancer letters.

[15]  B. Sopko,et al.  Environmental pollutant and potent mutagen 3-nitrobenzanthrone forms DNA adducts after reduction by NAD(P)H:quinone oxidoreductase and conjugation by acetyltransferases and sulfotransferases in human hepatic cytosols. , 2005, Cancer research.

[16]  B. Mahadevan,et al.  Carcinogenic polycyclic aromatic hydrocarbon‐DNA adducts and mechanism of action , 2005, Environmental and molecular mutagenesis.

[17]  J. Hudeček,et al.  The Anticancer Drug Ellipticine Forms Covalent DNA Adducts, Mediated by Human Cytochromes P450, through Metabolism to 13-Hydroxyellipticine and Ellipticine N2-Oxide , 2004, Cancer Research.

[18]  V. Arlt,et al.  3-aminobenzanthrone, a human metabolite of the environmental pollutant 3-nitrobenzanthrone, forms DNA adducts after metabolic activation by human and rat liver microsomes: evidence for activation by cytochrome P450 1A1 and P450 1A2. , 2004, Chemical research in toxicology.

[19]  D. Nebert,et al.  Oral exposure to benzo[a]pyrene in the mouse: detoxication by inducible cytochrome P450 is more important than metabolic activation. , 2004, Molecular pharmacology.

[20]  E. Frei,et al.  DNA adduct formation by the anticancer drug ellipticine and its hydroxy derivatives in human breast adenocarcinoma MCF-7 cells , 2004 .

[21]  E. Frei,et al.  DNA adduct formation by the anticancer drug ellipticine in rats determined by 32P postlabeling , 2003, International journal of cancer.

[22]  V. Arlt,et al.  Human enzymes involved in the metabolic activation of the environmental contaminant 3-nitrobenzanthrone: evidence for reductive activation by human NADPH:cytochrome p450 reductase. , 2003, Cancer research.

[23]  C. Wolf,et al.  Inactivation of the Hepatic Cytochrome P450 System by Conditional Deletion of Hepatic Cytochrome P450 Reductase* , 2003, The Journal of Biological Chemistry.

[24]  E. Frei,et al.  Rat microsomes activating the anticancer drug ellipticine to species covalently binding to deoxyguanosine in DNA are a suitable model mimicking ellipticine bioactivation in humans. , 2003, Chemical research in toxicology.

[25]  D. Phillips Smoking-related DNA and protein adducts in human tissues. , 2002, Carcinogenesis.

[26]  V. Arlt,et al.  Covalent binding of the anticancer drug ellipticine to DNA in V79 cells transfected with human cytochrome P450 enzymes. , 2002, Biochemical pharmacology.

[27]  E. Frei,et al.  The anticancer agent ellipticine on activation by cytochrome P450 forms covalent DNA adducts. , 2001, Biochemical pharmacology.

[28]  D. Phillips,et al.  Polycyclic aromatic hydrocarbons in the diet. , 1999, Mutation research.

[29]  R. E. Kouri,et al.  Relationships between aryl hydrocarbon hydroxylase inducibility and sensitivity to chemically induced subcutaneous sarcomas in various strains of mice. , 1973, Journal of the National Cancer Institute.